Although many big players like Pfizer, Merck and GlaxoSmithKline have gone backward this year, Novo Nordisk (NYSE: NVO) is emerging as a star, according to Steve Goldstein of MarketWatch. While the pharma giants face generic competition, shrinking pipelines and price pressures, the Danish drugmaker has a market capitalization approaching $39 billion, annual revenue of nearly $10 billion and 29,000 employees.
Goldstein explains that Novo is profiting as increasing number of people develop...